
Verve Therapeutics Announces Pipeline Progress And Reports First Quarter 2025 Financial Results
(MENAFN- GlobeNewsWire - Nasdaq) Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed …